Esperion Therapeutics (ESPR) Tops Q4 EPS by 9c

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($0.76), $0.09 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $18.18 million versus the consensus estimate of $20.57 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS says bull market has further to run
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance